In the current system of drug development, if a promising compound can't be patented, it is highly unlikely ever to make it to market — no matter how well it performs in the laboratory. The development of new cancer drugs is crippled as a result, says columnist Ralph W. Moss.
The reason: bringing a new drug to market is extremely expensive. Consider:
Publish date: 19 April 2007
The views expressed in the article are the author’s and are not necessarily shared by the members of the Foundation.